

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket No. PF112P2D1	Application Number 09/219,442
		HU et al.	
		Filing Date December 23, 1998	Group Art Unit 1646 1647

U.S. PATENT DOCUMENTS							
Examiner	Document Number	Date	Name	Class	SubClass	Filing Date	

FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	SubClass	Translation Yes/No	
B2	DZ 710696	9/30/99	Australia				
B2	EE 99/46364	9/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
B2	EF	Anderson, W.F. (1992) Science 256:808-813
	EG	Friedman, T. (1992) Nat. Genetics 2:93-98
	EH	Williams, R.S. (1993) Am. J. Med. Sci. 306:129-136
	EI	Hockel et al. (1993) Arch. Surg. 128:423-429
	EJ	Guzman et al. (1993) Circ. Res. 73:1202-1207

Examiner 	Date Considered 12-18-03
--------------	-----------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)				Complete If Known			
				Application Number.		09/219,442	
				Filing Date		December 23, 1998	
				First Named Inventor		Hu, et al.	
				Group Art Unit		1647	
				Examiner Name		Saoud, C. Landsman R	
				Attorney Docket Number		PF112P2D1	
Sheet	1		of	2			

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PL	EA	5,861,301	B1	Terman et al.	01-19-1999	
PL	EB	5,840,693	B1	Eriksson et al.	11-24-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
PL	EC	WO	99/46364	A1	Human Genome Sciences, Inc.	09-16-1999		
PL	ED	AU	AU-B-70128/96	A1	Genentech, Inc.	09-30-1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
PL	EE	ANDERSSON W.F., "Human gene therapy," <i>Science</i> , 256:808-813 (1992).	
	EF	FRIEDMAN, T., "A brief history of gene therapy," <i>Nat. Genetics</i> , 2:93-98 (1992).	
	EG	WILLIAMS, R.S. "Southwestern internal medicine conference: prospects for gene therapy of ischemic heart disease," <i>Am. J. Med. Sci.</i> , 306(2): 129-136 (1993).	
	EH	HOCKEL et al., "Therapeutic angiogenesis," <i>Arch. Surg.</i> , 128:423-429 (1993).	
	EI	GUZMAN et al. "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," <i>Circ. Res.</i> , 73:1202-1207 (1993).	
	EJ	BELLOMO et al., "Mice Lacking the Vascular Endothelial Growth Factor-B Gene (Vegfb) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ischemia," <i>Circ. Research</i> , 89(2): e29-e35 (2000).	
	EK	COCKERILL et al., "Angiogenesis: Models and Modulators" <i>Intl. Rev. Cytology</i> , 159:113-160 (1995).	
	EL	GAMBLE et al., "Regulation of In Vitro Capillary Tube Formation by Anti-Integrin Antibodies," <i>J. Cell. Bio.</i> , 121(4): 931-943 (1993).	
	EM	GOLDSPIEL et al., "Human Gene Therapy," <i>Clinical Pharmacy</i> , 12: 488-505 (1993).	
	EN	GRIMMOND et al., "Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor," <i>Genome Research</i> , 6:124-131 (1996).	

Examiner	Date Considered 12-18-03
----------	--------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)				Complete If Known			
				Application Number		09/219,442	
				Filing Date		December 23, 1998	
				First Named Inventor		Hu, et al.	
				Group Art Unit		1647	
				Examiner Name		Saoud, C.	
Sheet		2		of		2	
				Attorney Docket Number		PF112P2D1	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
BL	EO	HYDE <i>et al.</i> , "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," <i>Nature</i> , 362: 250-255 (1993).		
BL	EP	KAY <i>et al.</i> , "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> , 262:117-119 (1993).		
BL	EQ	KOLODKA <i>et al.</i> , "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer into Rat Hepatocytes in Vivo," <i>Somatic Cell and Molecular Genetics</i> , 19(5): 491-497 (1993).		
	ER	LITWIN <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> , 101-129.		
BL	ES	SHIBUYA <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> , 519-524 (1990).		
BL	ET	SILINS <i>et al.</i> , "Analysis of the Promoter Region of the Human VEGF-Related Factor Gene," <i>Biochem. Biophys. Res. Comm.</i> , 230: 413-418 (1997).		
BL	EU	STEWART <i>et al.</i> , "Insulin delivery by somatic cell gene therapy," <i>J of Mol. Endocrinology</i> , 11: 335-341 (1993).		
BL	EV	TOWNSON <i>et al.</i> , "Characterization of the Murine VEGF-Related Factor Gene," <i>Biochem. & Biophys. Res. Comms.</i> , 220: 922-928 (1996).		
	EW	WALSH <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> , 204: 289-300.		

Examiner	Date Considered 12.18.03
----------	--------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.